ERS Genomics
Finance · Ireland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Block E Iveagh Court Harcourt Rd, Dublin...Phone Number
+353 15390082Website
www.ersgenomics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About ERS Genomics
ERS Genomics is a global leader in providing access to foundational patents covering CRISPR/Cas9 intellectual property and licensing. The company offers worldwide access to an extensive portfolio of over 85 issued patents in more than 80 countries, essential for the practice of CRISPR/Cas9 gene editing. Their services are aimed at organizations and researchers looking to utilize CRISPR/Cas9 technology for transformative applications in gene editing. Co-founded by Nobel Prize winner Emmanuelle Charpentier, ERS Genomics plays a pivotal role in advancing gene editing technologies.Explore more
ERS Genomics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ERS Genomics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once ERS Genomics has new funding data
Check if ERS Genomics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on ERS Genomics recently announced quarterly report
Product Launch: Get notified when ERS Genomics launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at ERS Genomics
ERS Genomics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if ERS Genomics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if ERS Genomics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at ERS Genomics
Find more new buyers
Company Profile Activity
Activity Insights
ERS Genomics is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
ERS Genomics is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about ERS Genomics.
ERS Genomics Tech Stack
A closer look at the technologies used by ERS Genomics
Most Recent Scoops
Partnership
Project
Partnership, Product Development, Business Development, Intellectual Property, Legal Affairs, Bioengineering
Partnership
Partnership, Product Development, Product Management, Business Development, Intellectual Property, Legal Affairs, Bioengineering
Partnership
Partnership, Intellectual Property, Legal Affairs, Medical Research
New Hire
Executive Move
Executive Moves, New Hire
Partnership
Partnership, Research & Development, Product Management
ERS Genomics News & Media
ERS Genomics launches new Early Access Express License
New Early Access Express License provides streamlined, affordable access to foundational CRISPR/Cas9 intellectual property to early-stage innovators DUBLIN and CHESHIRE, England, Feb. 24, 2026 /PRNewswire/ -- ERS Genomics Limited ('ERS'), the CRISPR licensing company, today announced the...ERS Genomics and Dyadic Applied BioSolutions Sign CRISPR/Cas9 License Agreement
License enables Dyadic Applied BioSolutions to expand genetic engineering capabilities DUBLIN and JUPITER, Fla., Nov. 10, 2025 /PRNewswire/ -- ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology company producing...Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS GenomicsERS Genomics and Jumpcode Genomics sign CRISPR/Cas9 license agreement
License agreement provides Jumpcode Genomics access to CRISPR gene editing technology to enhance next-generation sequencing capabilities DUBLIN and SAN DIEGO, March 27, 2025 /PRNewswire/ -- ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Jumpcode Genomics ('Jumpcode'), a...
Read more news
Top Finance Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ERS Genomics
Sign Up For FreeTo access detailed company insights
ERS Genomics is a global leader in providing access to foundational patents covering CRISPR/Cas9 intellectual property and licensing. The company offers worldwide access to an extensive portfolio of over 85 issued patents in more than 80 countries, essential for the practice of CRISPR/Cas9 gene editing. Their services are aimed at organizations and... Read More
